Summary A murine ascites tumour was treated with intraperitoneal haematoporphyrin derivative (HPD) and laser light (lOmW, 514nm, Argon laser). HPD was given intraperitoneally 2 hours before 16 minute laser treatment. Uptake studies 2 hours after HPD injection showed 5-12 fold greater concentration of HPD in tumour cells than in 4 different normal tissues. A total of four HPD/laser treatments, given at 2 day intervals, resulted in 100% complete response; the cure rate was 85%. This study illustrates the effective use of intraperitoneal photodynamic therapy and opens the possibility of exploring different sensitizers, excitation wavelengths, and delivery systems in the treatment of human ascites tumours.
Single and multiple modality programmes have been used to treat human ovarian carcinoma (Young et al., 1982; Ozols et al., 1984a, b) . At present, ovarian carcinoma is the leading cause of gynaecologic cancer death in the USA with more than 11,000 women dying per year (Young et al., 1982) . Intraperitoneal drug therapy for ovarian cancer is experimentally interesting, yet, even though the results have been suggestive, no clear therapeutic advantage has been demonstrated. The combination of HPD injection and subsequent light exposure, referred to as photodynamic therapy (PDT) (Kessel, 1984) , has been a successful treatment modality for superficial malignancies of the skin (Vincent et al., 1981) , trachea and bronchus (Hayata et al., 1982; Cortese & Kinsey, 1982) , eye (Gomer et al., 1983) , bladder (Kelly & Snell, 1976) , and alimentary tract (Douglass et al., 1981) . Previously, we illustrated the feasibility of using PDT for ascites tumours (Tochner et al., 1985) ; now, we demonstrate that PDT can be extremely effective in a murine model and suggest it may have a role in the treatment of human ascites tumours. (Fekete & Ferringno, 1952 time was 16 min. To minimize sepsis, all mice were injected after each treatment with 0.2 ml of normal saline containing 1500 U of aqueous penicillin. Control mice were treated with either HPD or laser light alone. All mice were inspected and weighed daily. In the absence of a known assay for total HPD ether, the putative sensitizing agent, intracellular HPD levels were assessed by determining the total porphyrin concentration by a modification of Winkelman's method (Winkelman & Rasmussen-Taxdal, 1960) . In brief, tumour cells were removed from the peritoneal cavity, rinsed twice with PBS, sonicated, and suspended in an acetic acid/sodium acetate solution. The suspension was centrifuged (104RCF,4°C, 10min), the supernatant was removed, the pellet was extracted with diethyl ether, the ether layer was extracted with an aqueous HCI solution, and the aqueous HCI layer was assessed by absorbance (400 nm) and fluorescence (excitation 395/ emission 609nm) spectroscopy. Protein determinations were done by the dye-binding method (Bradford 1976) .
Materials and methods
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Results HPD levels were measured in tumour and normal tissues at various times after i.p. injection (Table I) . HPD concentrations were high in tumour cells after 2 h and remained elevated for 72 h. Both kidney and liver contained substantial levels of porphyrin, corroborating previous studies (Douglass et al., 1981) . Figure 1 shows the weight gain characteristics of tumour-bearing mice after PDT; the weights of the treated mice fell below that of subcutaneously, mice died quickly. Figure 2 also illustrates that there were no early deaths from treatment-related bowel perforation or sepsis; either complication is a major concern of percutaneous puncture and probing of the abdominal cavity (Tochner et al., 1985) . Five mice that had been cured of their initial tumour by PDT were reinjected with 2 x 105 tumour cells. Once again, these mice developed tumour, and the rate of tumour growth was the same as the initial tumour growth. This control was performed to establish that the peritoneum had not been damaged to the extent of compromising tumour growth by some nutritional mechanism.
Discussion
The biological characteristics of this particular tumour (ascitic peritoneal spread, tumour deposits < 3 mm, and only slight penetration into the diaphragm (Fekete & Ferringno, 1952 )) provides a model to illustrate that tumour spread into pockets of the peritoneum can be effectively treated by PDT. Since diaphragmatic and serosal surface implantations are frequent sites of initial intraperitoneal carcinomatosis in humans (Young et al., 1982) , PDT may have a clinical role. Moreover, in this study, less penetrating 514 nm laser light was used rather than the usual 630 nm reported for most HPD based PDT studies. There may be an advantage to treatment at 514nm light for nonsolid tumours (Bellnier et al., 1985) : depth of light penetration into the tumour is of less importance, and HPD absorbance is three times greater at 514 than at 630 nm. Greater light absorbance should result in greater singlet oxygen production and better tumour kill. Normally, tumours are treated 48-72 h after HPD injection. The rationale for delayed laser treatment is that at 48-72h there is a greater differential retention of HPD in solid tumours than normal tissue (Dougherty et al., 1978) ; however, we treated tumours earlier, 2h after HPD i.p. injection, because in our model there is excellent early HPD uptake by the ascites tumour cells. Were tumour nodules within the peritoneal cavity larger, more conventional protocols may have been required (Kessel, 1984) .
Previously, we have shown the feasibility of PDT for intraperitoneal tumours (Tochner et al., 1985) . In this study, we have achieved an 85% cure by increasing the frequency and number of treatments. There is one previous study which allows comparison of PDT to relative effective chemotherapy (Ozols et al., 1979) . In that study, the same murine tumour model was used, and treatment by i.p. adriamycin at different times after tumour transplantation was investigated. The authors achieved a 70% cure in one subset, but only if adriamycin injections were made as early as 48 h after tumour transfer. If they waited longer, when the tumour burden was greater -as we did in this study -less than 20% cure was achieved. Frequent treatments could not be used because of the inherent systemic toxicity of adriamycin. We have achieved an 85% cure with fractionated treatments, and further, if tumour seeding had not occurred along the laser fibre track, it is possible that a 100% cure would have been achieved. Tumour spreading into the subcutaneous space is a technical complication that may be better studied in larger animals. Although our results of high percentage of cures for an ascites tumour are promising, the treatment of human ovarian carcinoma, which frequently involves large tumour deposits (>3 mm), may not respond to treatment with 514nm light. The efficacy of treating such tumours with greater tissue-penetrating, longer wavelength light needs to be studied. We are currently studying longer wavelength absorbing sensitizers for treatment of ascites tumours and intraperitoneal solid tumours. At present, we conclude from the work presented in this study that (a) HPD based PDT appears to be more effective than i.p. chemotherapy for ascites tumours, and (b) PDT should be studied in larger animals with the ultimate aim of evaluating its efficacy for primary or adjuvant treatment of human malignant ascites tumours such as ovarian carcinoma.
